KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1–positive advanced, relapsed or refractory solid tumor or lymphoma.

Authors

null

Birgit Geoerger

Gustave Roussy, Villejuif, France

Birgit Geoerger , Hyoung Jin Kang , Michal Yalon-Oren , Lynley V. Marshall , Catherine Vezina , Alberto S. Pappo , Theodore Willis Laetsch , Antonio Sergio Petrilli , Martin Ebinger , Jacek Toporski , Julia Glade-Bender , Wayne Nicholls , Elizabeth Fox , Steven G. DuBois , Margaret Macy , Susan Lerner Cohn , Kumudu Pathiraja , Scott J. Diede , Scot Ebbinghaus , Navin R. Pinto

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Pediatric Solid Tumors

Clinical Trial Registration Number

NCT02332668

Citation

J Clin Oncol 36, 2018 (suppl; abstr 10525)

DOI

10.1200/JCO.2018.36.15_suppl.10525

Abstract #

10525

Poster Bd #

198

Abstract Disclosures

Similar Posters

First Author: Diwakar Davar

First Author: Panpan Zhang